⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9225357 | 0.90 | — | — | |
| SCHEMBL11673856 | 0.90 | SIGMAR1 (0.39) | — | |
| SCHEMBL19922821 | 0.88 | — | — | |
| SCHEMBL9085332 | 0.88 | SIGMAR1 (0.42) | — | |
| SCHEMBL4559904 | 0.88 | — | — | |
| SCHEMBL6949947 | 0.88 | SIGMAR1 (0.42) | — | |
| SCHEMBL3691804 | 0.88 | — | — | |
| SCHEMBL7909688 | 0.87 | CYP1A2 (0.46) | — | |
| SCHEMBL11021457 | 0.85 | CYP1A2 (0.56) | — | |
| SCHEMBL11019093 | 0.85 | CYP1A2 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957181-B2 | Preparation process for cyclic conjugated polymer and polymerization catalyst for cyclic conjugated polymer | SOKEN CHEMICAL & ENGINEERING CO., LTD. (JP) | 2015-02-17 | — | — | US | claimed |
| US-20250288587-A1 | Methods of Treating Fibrosis | ATHIRA PHARMA, INC. (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250275976-A1 | Methods of Treating Neuroinflammatory Conditions | ATHIRA PHARMA, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250275975-A1 | Methods of Treating Neuropathies | ATHIRA PHARMA, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250161308-A1 | Methods of Treating Covid-Related Disorders | ATHIRA PHARMA, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| CN-119684295-A | Bicyclic compounds for treating diseases and uses thereof | 雅斯娜制药公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-4518865-A1 | METHODS OF TREATING NEUROINFLAMMATORY CONDITIONS | Athira Pharma, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4518866-A1 | METHODS OF TREATING FIBROSIS | Athira Pharma, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4518864-A1 | METHODS OF TREATING NEUROPATHIES | Athira Pharma, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20250041307-A1 | Uses of Bicyclic Compounds for the Treatment of Diseases | ATHIRA PHARMA, INC. (US) | 2025-02-06 | — | — | US | disclosed |
| WO-2008060789-A2 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-05-22 | — | — | WO | disclosed |
| CN-101184761-A | Spiro-indolone compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2008-05-21 | — | — | CN | disclosed |
| EP-1888595-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-02-20 | — | — | EP | disclosed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
| WO-2006110917-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-19 | — | — | WO | disclosed |
| EP-1592426-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| US-5405997-A | Stable against rapid metabolism | THE UPJOHN COMPANY (US) | 1995-04-11 | — | — | US | disclosed |